Eagle LogoPEPTIDE INITIATIVE

Peptide Database

Adipotide
Weight Management
AOD-9604
Weight Management
BPC-157
Healing & Recovery
Cagrilintide
Weight Management
CJC-1295
Growth Hormone
DSIP
Sleep & Recovery
Epithalon
Anti-Aging
GHK-Cu
Anti-Aging
GHRP-2
Growth Hormone
HCG
Hormone Support
Hexarelin
Growth Hormone
HGH
Growth Hormone
IGF-1 LR3
Growth Hormone
Kisspeptin
Hormone Support
Melanotan-2
Cosmetic
MOTS-C
Metabolic
NAD+
Anti-Aging
Oxytocin Acetate
Hormone Support
PEG-MGF
Recovery
PT-141
Sexual Health
Retatrutide
Weight Management
Selank
Cognitive
Semaglutide
Weight Management
Semax
Cognitive
Sermorelin
Growth Hormone
Snap-8
Cosmetic
SS-31
Mitochondrial
TB-500
Healing & Recovery
Tesamorelin
Growth Hormone
Thymosin Alpha-1
Immune
Tirzepatide
Weight Management
Total Peptides: 31
Back to Home
Kisspeptin
EfficacyHigh
Studies8
Participants187
StatusAvailable

Kisspeptin

Kisspeptin-54 / Kisspeptin-10

Kisspeptin is a neuropeptide encoded by the KISS1 gene that plays a critical role in regulating the hypothalamic-pituitary-gonadal (HPG) axis. It stimulates gonadotropin-releasing hormone (GnRH) secretion by binding to the GPR54/Kiss1R receptor, making it essential for reproductive function, puberty onset, and fertility. Originally discovered as a metastasis suppressor in certain cancers, kisspeptin has emerged as a promising therapeutic target for reproductive disorders including infertility, hypothalamic amenorrhea, and hypoactive sexual desire disorder.

Complete Research Database

Clinical Research Outcomes

IVF Clinical Trial 2014

Female, 32, Infertility Patient

Successful pregnancy after kisspeptin-triggered IVF cycle
“After years of failed IVF attempts, kisspeptin finally helped us conceive naturally without the severe side effects of previous treatments.”
Part of 53-woman trial with 23% pregnancy success rate, experienced no ovarian hyperstimulation
Hypothalamic Amenorrhea Study 2014

Female, 24, Athlete with Amenorrhea

Restored menstrual cycles after 8 weeks of twice-weekly treatment
“My periods came back for the first time in 2 years - I felt like my body was functioning normally again.”
LH levels increased from 0.8 to 12.4 IU/L, maintained regular cycles for 6 months post-treatment
HSDD Research Trial 2022

Female, 29, Hypoactive Sexual Desire Disorder

Improved sexual brain processing and attraction response
“The brain scans showed my attraction centers lighting up again - it felt like rediscovering a part of myself.”
fMRI showed enhanced activity in sexual processing regions with no adverse effects during 75-minute infusion

Clinical Outcome Measures

+90.0
🥚 Oocyte Maturation
(from 85.0 baseline)
+23.0
🤰 Pregnancy Rate
(from 15.0 baseline)
+400.0
💗 LH Response
(from 100.0 baseline)
+35.0
🧠 Sexual Processing
(from 100.0 baseline)
+85.0
🔄 Cycle Restoration
(from 0.0 baseline)
Clinical outcome measures

Cardiovascular & Metabolic Outcomes

Blood Pressure Reduction

-6.7 mmHg systolic
Statistical significance: p<0.001
Reduced hypertension medication needs

Triglycerides

-31.5% reduction
Statistical significance: p<0.001
Significant cardiovascular risk improvement

HDL Cholesterol

+8.3% increase
Statistical significance: p<0.01
Improved lipid profile

Waist Circumference

-19.4 cm reduction
Statistical significance: p<0.001
Reduced visceral adiposity

C-Reactive Protein

-41.2% reduction
Statistical significance: p<0.001
Decreased systemic inflammation

Sleep Apnea Events

-58% reduction in AHI
Statistical significance: p<0.001
Improved sleep quality and oxygenation

Medical Disclaimer

Kisspeptin is in Phase 2 clinical trials for reproductive applications. This information is for educational purposes only and should not be construed as medical advice. Any clinical use should occur only under medical supervision in approved research or clinical settings.